Ionis Pharmaceuticals has moved closer to its first fully owned blockbuster drug after the US Food and Drug Administration (FDA) expanded approval for Tryngolza (olezarsen) in severe hypertriglyceridemia (sHTG). The decision strengthens the drug’s commercial trajectory, expands its patient reach
